Cernostics
Total Raised
$21.34MInvestors Count
9Deal Terms
3Funding, Valuation & Revenue
13 Fundings
Cernostics has raised $21.34M over 13 rounds.
Cernostics's latest funding round was a Acquired for on October 19, 2021.
Cernostics's latest post-money valuation is from October 2021.
Sign up for a free demo to see Cernostics's valuations in October 2021 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/19/2021 | Acquired | 3 | ||||
8/13/2021 | Unattributed - II | $5.98M | Undisclosed Investors | 1 | ||
3/21/2018 | Unattributed VC - III | $2.5M | 3 | |||
8/31/2016 | Unattributed VC - II | |||||
10/29/2015 | Grant |
Date | 10/19/2021 | 8/13/2021 | 3/21/2018 | 8/31/2016 | 10/29/2015 |
|---|---|---|---|---|---|
Round | Acquired | Unattributed - II | Unattributed VC - III | Unattributed VC - II | Grant |
Amount | $5.98M | $2.5M | |||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 3 | 1 | 3 |
Cernostics Deal Terms
3 Deal Terms
Cernostics's deal structure is available for 3 funding rounds, including their Acquired from October 19, 2021.
Round | Acquired | Unattributed VC - II | Series B |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired | |||||||||||||||
Unattributed VC - II | |||||||||||||||
Series B |
Cernostics Investors
9 Investors
Cernostics has 9 investors. Castle Biosciences invested in Cernostics's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/19/2021 | 10/19/2021 | 1 Acquired | Corporation | Texas | ||
Venture Capital | California | |||||
Venture Capital | Pennsylvania | |||||
Corporation | Pennsylvania | |||||
Government | Maryland |
First funding | 10/19/2021 | ||||
|---|---|---|---|---|---|
Last Funding | 10/19/2021 | ||||
Investor | |||||
Rounds | 1 Acquired | ||||
Board Seats | |||||
Type | Corporation | Venture Capital | Venture Capital | Corporation | Government |
Location | Texas | California | Pennsylvania | Pennsylvania | Maryland |
Compare Cernostics to Competitors
Lucid Diagnostics involves in cancer prevention medical diagnostics within the healthcare sector. The company provides the EsoGuard DNA test, a diagnostic tool for detecting esophageal precancer, and the EsoCheck esophageal cell collection device, which is used to collect samples for testing. Lucid Diagnostics serves the healthcare industry, focusing on patients at risk of developing esophageal cancer. It was founded in 2018 and is based in New York, New York.
Previse is a biotechnology company focused on cancer detection and prevention within the healthcare sector. The company offers a molecular test, EsopredictTM, which provides guidance for surveillance and treatment decisions in patients with Barrett's esophagus, a precancerous condition. Previse's solutions aim to help healthcare providers and patients understand and manage the risk of progressing to esophageal cancer. Previse was formerly known as Capsulomics. It was founded in 2018 and is based in Halethorpe, Maryland. In May 2025, Previse was acquired by Castle Biosciences.
Loading...